SCHEMBL22186263

SCHEMBL22186263

CC(C)(C)OC(=O)NC(CCC(=O)OC(=O)OC(C)(C)C)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 11/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
CTSS P25774 5/20 0.40
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CYP2D6 P10635 1/20 0.38
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
REN P00797 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
CAPN1 P07384 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27541323 0.88 CTSK (0.47) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL14539748 0.88 CTSK (0.47) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL14539642 0.88 CTSK (0.47) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL20608551 0.87 CTSK (0.46) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL27370835 0.87 CTSK (0.46) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL11169650 0.87 CTSK (0.46) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL22186265 0.85 CYP2D6 (0.42) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL13263354 0.83 CTSK (0.44) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL11165568 0.83 CTSK (0.46) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL7509222 0.82 CTSK (0.47) CTSKCYP1A2CYP2C9CYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3618833-B1 TRIPARTITE ANDROGEN RECEPTOR ELIMINATORS, METHODS AND USES THEREOF SPG THERAPEUTICS INC (US) 2022-01-19 EP disclosed
US-20200207753-A1 Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof SPG THERAPEUTICS, INC. (US) 2020-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207753-A1 Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof AR, ESRRA, ESRRB CTSK 3019/4885CYP1A2 900/4885CYP2C9 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.